Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer

BACKGROUND: Combination therapy with the B-Raf inhibitor, dabrafenib, and the MEK inhibitor, trametinib (DT) is commonly used to treat patients with B-Raf proto-oncogene, serine/threonine kinase V600E (BRAF V600E)-mutated non-small cell lung cancer (NSCLC). However, the mechanisms through which canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirai, Noriko, Hatanaka, Yutaka, Hatanaka, Kanako C., Uno, Yuji, Chiba, Shin-Ichi, Umekage, Yasuhiro, Minami, Yoshinori, Okumura, Shunsuke, Ohsaki, Yoshinobu, Sasaki, Takaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512466/
https://www.ncbi.nlm.nih.gov/pubmed/34733624
http://dx.doi.org/10.21037/tlcr-21-415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512466/
https://www.ncbi.nlm.nih.gov/pubmed/34733624
http://dx.doi.org/10.21037/tlcr-21-415

Ejemplares similares